Aetna considers romiplostim (Nplate™) medically necessary for the treatment of thrombocytopenia in members with chronic immune (idiopathic) thrombocytopenic purpura (ITP) whose degree of thrombocytopenia (platelet count less than 30,000/mm3) and clinical condition (active bleeding or risk factors for bleeding (such as, but not limited to, hypertension, peptic ulcer disease, anticoagulation, recent surgery, head trauma)) increases the risk for bleeding and who have had an insufficient response to corticosteroids (eg, prednisone, methylprednisolone, dexamethasone) or immunoglobulins (IVIG, anti-D (WinRho)).
Aetna considers romiplostim experimental and investigational for the following indications (not an all-inclusive list) because its effectiveness for these indications has not been established:
Romiplostim (NplateTM, Amgen, Inc., Thousand Oaks, CA), a thrombopoietin receptor agonist that stimulates bone marrow megakaryocytes to produce platelets, was approved by the Food and Drug Administration (FDA) on August 22, 2008 for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. The FDA-approved labeling states that romiplostim should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding and that it should not be used to normalize platelet counts.
The safety and efficacy of romiplostim were assessed in 2 double-blind, placebo-controlled clinical studies of 125 adult patients with chronic ITP and in an open-label extension study. In these studies, treatment with romiplostim resulted in dose-dependent increases in platelet counts. After a single subcutaneous dose of 1 to 10 mcg/kg of romiplostim, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2- to 3-week period. The platelet counts were above 50 x 10(9)/L for 7 out of 8 patients with chronic ITP who received 6 weekly doses of romiplostim at 1 mcg/kg.
Kuter et al (2008) assessed the long-term effects of romiplostim in splenectomized and non-splenectomized patients with ITP in 2 parallel trials. A total of 63 splenectomized and 62 non-splenectomized patients with ITP with a mean of 3 platelet counts of 30 x 10(9)/L or less were randomly assigned 2:1 to subcutaneous injections of romiplostim (n = 42 in the splenectomized study and n = 41 in the non-splenectomized study) or placebo (n = 21 in both studies) every week for 24 weeks. Doses of romiplostim were adjusted to maintain platelet counts of 50 x 10(9)/L to 200 x 10(9)/L. The primary objectives were to assess the efficacy of romiplostim as measured by a durable platelet response (platelet count greater than or equal to 50 x 10(9)/L during 6 or more of the last 8 weeks of treatment) and treatment safety. The authors reported that a durable platelet response was achieved by 38 % (16/42) of the splenectomized patients given romplostim versus none (0/21) of the placebo patients, and by 61 % (25/41) of the non-splenectomized patients given romplostim versus 0.05 % (1/21) given placebo. Eighty-seven percent (20/23) of patients given romiplostim (12/12 splenectomized and 72 % (8/11) non-splenectomized patients) reduced or discontinued concurrent therapy compared with 38 % (6/16) of those given placebo (1/6 splenectomized and 5/10 non-splenectomized patients). Adverse events were reported to be similar in both groups. Furthermore, no antibodies against romiplostim or thrombopoietin were detected. The authors concluded that romiplostim was well-tolerated and increased and maintained platelet counts in splenectomized and non-splenectomized patients with ITP and that many patients were able to reduce or discontinue other ITP medications.
Following completion of the placebo-controlled studies, 100 patients entered an extension study of long-term romiplostim therapy. The majority of patients maintained platelet counts of 50,000/mcL or greater throughout the study with a median duration of romiplostim treatment of 60 weeks and a maximum duration of 96 weeks.
The major safety concerns consisted of risks for bone marrow reticulin formation and worsened thrombocytopenia (compared to baseline) following romiplostim discontinuation. Other potential risks include marrow fibrosis during long-term therapy or thromboses due to excessive platelet increases.
The recommended initial dose of romiplostim is 1 mcg/kg as a subcutaneous injection; then as a once-weekly dose adjusted by increments of 1 mcg/kg, not to exceed 10 mcg/kg per week, to achieve a platelet count of greater than 50,000/mcL as necessary to reduce the risk for bleeding. In clinical studies, most patients who responded to romiplostim achieved and maintained platelet counts of 50 x 10(9)/L or more with a median dose of 2 mcg/kg.
Romiplostim should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum weekly dose of 10 mcg/kg.
Romiplostim may be used with other ITP therapies, such as corticosteroids, danazol, azathioprine, intravenous immunoglobulin, and anti-D immunoglobulin. If the patient's platelet count is 50 x 10(9)/L or greater, medical ITP therapies may be reduced or discontinued.
According to the FDA (2008), in a single-arm trial investigating the use of romiplostim in myelodysplasic syndromes (MDS), 11 of 44 patients were reported as having possible disease progression, among whom 4 patients developed acute myelogenous leukemia. Randomized, controlled studies are needed to determine the risks and benefits of romiplostim in these patients. In the controlled studies of patients with chronic ITP, the incidence of hematologic malignancies was low and similar between romiplostim and placebo. Romiplostim is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.
Kantarjian and colleagues (2010) evaluated the safety and effectiveness of romiplostim for treatment of thrombocytopenic patients with MDS. Eligible patients had lower-risk MDS (International Prognostic Scoring System low or intermediate 1), a mean baseline platelet count less than or equal to 50 x 10(9)/L, and were only receiving supportive care. Patients received 3 injections of 300, 700, 1,000, or 1,500 microg romiplostim at weekly intervals. After evaluation of platelet response at week 4, patients could continue to receive romiplostim in a treatment extension phase for up to 1 year. All 44 patients who enrolled completed the treatment phase; 41 patients continued into the extension phase. Median platelet counts increased throughout the study, from fewer than 30 x 10(9)/L at baseline to 60, 73, 38, and 58 x 10(9)/L at week 4 for the 300-, 700-, 1,000-, and 1,500 -microg dose cohorts, respectively. A durable platelet response (per International Working Group 2000 criteria for 8 consecutive weeks independent of platelet transfusions) was achieved by 19 patients (46 %). The incidence of bleeding events and platelet transfusions was less common among patients who achieved a durable platelet response than those who did not (4.3 versus 39.3 per 100 patient-weeks). Forty-three patients (98 %) reported 1 or more adverse events. Treatment-related serious adverse events were reported in 5 patients (11 %), all of whom were in the 1,500-microg dose cohort. Two patients progressed to acute myeloid leukemia during the study. No neutralizing antibodies to either romiplostim or endogenous thrombopoietin were seen. The authors concluded that romiplostim appeared well-tolerated in this study and may be a useful treatment for patients with MDS and thrombocytopenia. The key drawback of this study was the lack of a control group. These investigators stated that ongoing randomized controlled trials and future combination studies will optimize the dose schedules of romiplostim and define its precise therapeutic role in MDS.
Vadhan-Raj (2009) stated that despite the extensive efforts in the clinical development of thrombopoietic agents in the past decade, recombinant interleukin-11 (IL-11) is the only agent currently approved by the FDA for thrombocytopenia induced by chemotherapy. The use of this agent is limited due to its narrow therapeutic index. While promising biologic activity was observed with recombinant thrombopoietins (TPOs) in non-myeloablative clinical settings, further clinical development was halted due to evidence of neutralizing antibodies to pegylated recombinant human megakaryocyte growth and development factor. Recently, a number of novel TPO receptor agonists have been developed with promising clinical activity and a lesser potential for immunogenicity. Several of these second-generation platelet-stimulating agents are currently in clinical development, including peptide (romiplostim) and non-peptide (eltrombopag and AKR501) mimetics. The clinical trials of romiplostim and eltrombopag are currently ongoing to optimize their dose and schedule in ameliorating chemotherapy-induced thrombocytopenia.
In a phase II, multi-center, open-label study, Sekeres et al (2011) examined the effects of subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk MDS. A total of 28 thrombocytopenic patients with lower risk MDS were assigned to receive romiplostim 750 μg administered subcutaneously either weekly or bi-weekly or administered as bi-weekly intravenous injections for 8 weeks. Patients also could enter a 1-year study extension phase. At least 1 adverse event was observed in 93 % of patients. The most common adverse events were fatigue and headache (18 % for both, and 5 events were grade 3 or 4. There was 1 serious treatment-related adverse event in the bi-weekly intravenous cohort (hypersensitivity). This hypersensitivity resolved without discontinuation of study treatment. No patients developed neutralizing antibodies or bone marrow fibrosis. Of the patients who completed 8 weeks of treatment, 57 % had a complete platelet response, an additional 8 % had a major platelet response, and 61 % did not require a platelet transfusion during this period. Weekly subcutaneous injections achieved the highest mean trough concentrations. The authors concluded that the safety and efficacy profiles of romiplostim in this study suggested that weekly subcutaneous administration of 750 μg romiplostim is an appropriate starting dose for future clinical studies in patients with MDS and thrombocytopenia.
Kuter (2011) noted that thrombocytopenia is a common clinical problem associated with a wide range of medical conditions including ITP, chemotherapy-induced thrombocytopenia (CIT), hepatitis C-related thrombocytopenia, and MDS. Until recently, the only treatments for thrombocytopenia were to alleviate the underlying cause or to provide platelet transfusions. With the discovery and recent clinical availability of TPO mimetics, a new treatment option has emerged. Two TPO mimetics are currently clinically available for treating ITP: romiplostim (an injectable peptide TPO mimetic) and eltrombopag (a non-peptide, orally available TPO mimetic). The author reviewed the development, biology, and clinical trials with romiplostim. With few adverse effects, romiplostim is effective in raising the platelet count in over 80 % of ITP patients, allowing them to discontinue other therapies, reduce the need for splenectomy, and improve their quality of life. Long-term theoretical side effects of romiplostim treatment include reticulin formation, thrombo-embolism, and antibody formation to romiplostim. A practical way of using romiplostim is provided: a higher starting dose of 3 mg/kg is recommended along with efforts to avoid withholding the dose. The author concluded that future studies are needed to evaluate the utility of romiplostim in CIT, hepatitis-C related thrombocytopenia, and MDS.
In a review on "Novel agents and approaches for stem cell mobilization in normal donors and patients", Bakanay and Demirer (2012) listed thrombopoietin-receptor agonists including romiplostim as one of the investigational agents. They noted that in the future, thrombopoietin-receptor agonists may be potential adjuncts to granulocyte colony-stimulating factor in poor mobilizers.
Evans syndrome is an autoimmune disorder characterized by the simultaneous or sequential development of autoimmune hemolytic anemia and immune thrombocytopenia. It may be primary (idiopathic), or associated with other diseases. First-line therapy is immunosupression; and 2nd-line therapy includes danazol and splenectomy. Gonzalez-Nieto et al (2011) reported a case of a man diagnosed with systemic lupus erythematosus, associated anti-phospholipid syndrome and Evans syndrome, who developed a severe thrombocytopenia refractory to treatment with first-line drugs, cyclophosphamide and rituximab, and who responded to romiplostim with a normalization of the platelet recount, which later enabled a therapeutic splenectomy to be performed. Moreover, UpToDate reviews on "Treatment of autoimmune hemolytic anemia: Warm agglutinins" (Rosse and Schrier, 2012) and "Autoimmune hemolytic anemia in children" (Ware, 2012) do not mention the use of romiplostim as a therapeutic option.
Ruiz-Delgado et al (2011) stated that thrombocytopenia ensuing during acute graft-versus-host disease (GVHD) is multi-factorial and may significantly compromise the prognosis of the patient; non-immune persistent thrombocytopenia has been considered as an adverse prognostic factor in GVHD. These investigators described the case of a 10-year old girl who developed steroid-refractory thrombocytopenia and who responded promptly to the subcutaneous delivery of romiplostin. The authors noted that to the best of their knowledge, this is the first description of the usefulness of the peptibody in the setting of GVHD. However, UpToDate reviews on "Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease" (Chao, 2012a),"Treatment of chronic graft-versus-host disease" (Chao, 2012b), and "Treatment of acute graft-versus-host disease: Clinical trials" (Chao, 2012c) do not mention the use of romiplostim as a therapeutic option.
Giagounidis and colleagues (2014) evaluated the effectiveness of romiplostim in patients who had thrombocytopenia with low-risk/intermediate-1-risk MDS. Patients who had thrombocytopenia with low-risk/intermediate-1-risk MDS (n = 250) were randomized 2:1 to receive romiplostim or placebo weekly for 58 weeks. The primary end-point was the number of clinically significant bleeding events (CSBEs) per patient-had a hazard ratio for romiplostim : placebo of 0.83 (95 % confidence interval [CI], 0.66 to 1.05; p = 0.13). Clinically significant bleeding events were reduced significantly in the romiplostim group for patients who had baseline platelet counts greater than or equal to 20 × 10(9) /L (p < 0.0001). For patients who had baseline platelet counts less than 20 × 10(9) /L, there was no difference in the number of CSBEs, but the platelet transfusion rates were higher in the placebo group (p < 0.0001), which may have affected the overall CSBE results in this group with severe thrombocytopenia. The incidence of bleeding events was reduced significantly in the romiplostim group (relative risk, 0.92), as were protocol-defined platelet transfusions (relative risk, 0.77). Platelet response rates according to 2006 International Working Group criteria were higher for the group that received romiplostim (odds ratio, 15.6). On the basis of interim data, an independent data monitoring committee advised halting study drug because of concerns regarding excess blasts and AML rates with romiplostim (interim hazard ratio, 2.51). At 58 weeks, the acute myeloid leukemia (AML) rates were 6 % in the romiplostim group and 4.9 % in the placebo group (hazard ratio, 1.20; 95 % CI: 0.38 to 3.84), and the overall survival (OS) rates were similar. The authors concluded that romiplostim treatment in patients with low-risk/intermediate-1-risk MDS increased platelet counts and decreased the number of bleeding events and platelet transfusions. Although study drug was discontinued because of an initial concern of AML risk, survival and AML rates were similar with romiplostim and placebo.
Buccoliero et al (2014) described a case of a 64-year old man with a history of ITP which had required several treatments including splenectomy, and with chronic hepatitis C virus (HCV) infection untreated due to severe thrombocytopenia. In March 2011, platelet count was 14,000/mmc and a thrombopoietic therapy with romiplostim was initiated at the dose of 2 ug/kg/week that was increased to 8 ug/kg/week. At week 32, platelet count was 65,000/mmc and an anti-HCV therapy with peginterferon and ribavirin was then started. At baseline laboratory tests indicated AST 99 IU/l, ALT 125 UI/l, HCV_RNA 3,220 UI/ml and HCV genotype 2a/2c. An early virological response (EVR) with normalization of transaminases in the course of anti-viral therapy, such as a sustained virological response (SVR) after its interruption were recorded. Therefore, a satisfactory platelet count (range of 54,000 to 179,000/mmc) at the dose of 4 ug/week during anti-viral therapy, such as at the dose of 2 ug/kg/week after anti-viral interruption (range 65,000 to 292,000/mmc) was recorded. Romiplostim proved safe and effective in the course of anti-viral treatment. Therefore, it permitted the start of anti-HCV therapy despite severe thrombocytopenia and also avoided any peg-interferon dosage modification or discontinuation. The authors stated that further prospective studies in larger patient cohort should be encouraged to validate this strategy.
Parameswaran et al (2014) reported on a series of 20 patients who had protracted CIT and were treated with romiplostim. These researchers performed a retrospective review of the use of romiplostim for dose-limiting CIT at Memorial Sloan-Kettering Cancer Center from 2010 to 2012 Romiplostim was initiated at 1 to 2 ug/kg weekly, with dose escalation by 1 ug/kg per week until recovery of platelets (greater than or equal to 100 × 10(9)/L). If patients resumed chemotherapy, weekly romiplostim was continued. Romiplostim improved platelet counts in all 20 patients. In 19 of 20 patients, platelet counts of greater than or equal to 100 × 10(9)/L were achieved. The mean dose of romiplostim to achieve adequate platelet recovery was 2.9 ug/kg (range of 1.0 to 5.1); 16 patients achieved platelet recovery by 2 weeks. Fifteen patients resumed cytotoxic chemotherapy with continued romiplostim support and 14 tolerated at least 2 subsequent cycles of chemotherapy, on schedule, without recurrence of dose-limiting CIT. Sepsis prevented continued chemotherapy in 1 patient. No resistance to romiplostim was observed. Three deep vein thromboses (DVT) were observed; 1 of which was a recurrent DVT in a patient who had previously experienced a DVT and was off anti-coagulation. Three DVTs within 20 patients is within the anticipated thrombosis rates of patients with active cancer on chemotherapy. The authors concluded that romiplostim resulted in improvement in platelet counts, allowing resumption of chemotherapy without recurrence of dose-limiting CIT. No treatment-related toxicity was observed, but this would need to be confirmed in a larger, prospective trial. They stated that their series differed from prior studies in that they selected only those patients who had already demonstrated persistent thrombocytopenia, and they continued weekly romiplostim during chemotherapy. Romiplostim may be a safe and effective treatment for CIT.
Yamada and associates (2014) reported on the case of a woman in her 60s who was referred to the authors’ department with advanced rectal cancer and multiple unresectable metastases of the liver and peritoneum. She had been diagnosed with ITP in her 20s, with a platelet count maintained at approximately 1.0×10(4)/μL by prednisolone; on admission, her platelet count was 0.9×10(4)/μL. Romiplostim was administered prior to chemotherapy. Her platelet count increased to about 10.0×10(4)/μL during chemotherapy with oxaliplatin plus capecitabine, and she developed DVT requiring inferior vena cava filter placement and anti-coagulation. No other severe adverse events occurred. The authors noted that there is no standard regimen for the treatment of solid tumors in patients with ITP. This was the first reported case of the concomitant use of romiplostim and chemotherapy for advanced rectal cancer.
Prica et al (2014) stated that thrombocytopenia is common (40 to 65 %) and potentially serious in MDS. These investigators performed a systematic review to determine the safety and effectiveness of adding a thrombopoietin-receptor (THPO-R) agonist to standard MDS treatment. MEDLINE, EMBASE and CENTRAL databases were searched. These researchers included randomized controlled trials (RCTs) comparing a THPO-R agonist to placebo. A meta-analysis of the effects was performed. End-points included bleeding and platelet transfusion rates, risk of progression to AML and mortality. A total of 384 patients from 5 trials were included, 4 using romiplostim and 1 using eltrombopag. Overall, the relative risk (RR) of bleeding with romiplostim versus placebo was 0.84 [95 % CI: 0·57 to 1.24]. However, compared to placebo, romiplostim significantly decreased the exposure-adjusted bleeding rate (RR 0.92; 95 % CI: 0.86 to 0.99), as well as the exposure-adjusted platelet transfusion rate (RR 0.69; 95 % CI: 0.53 to 0.88). The RR of AML progression with romiplostim was 1.36 (95 % CI: 0.54 to 3·40), however the outcome data were judged as higher risk of bias. The authors concluded that romiplostim is promising in its ability to decrease patient-important outcomes: bleeding and platelet transfusion need. Moreover, they stated that although the risk of AML progression was not increased, due to unclear risk of bias in the data, this safety concern is difficult to assess. These investigators stated that romiplostim cannot yet be routinely recommended.
Furthermore, National Comprehensive Cancer Network’s clinical practice guideline on “Myelodysplastic syndromes” (Version 1.2016) states that “Phase I/II studies with romiplostim showed promising rates of platelet response (46 % - 65 %) in patients with lower-risk MDS …. It should be noted that neither romiplostim nor eltrombopag”.
Thrombocytopenia during Pregnancy:
Decroocq et al (2014) stated that primary immune thrombocytopenia is not a rare event during pregnancy, and it must be carefully managed to avoid hemorrhagic complications for the mother. After failure of first-line treatments, the teratogenicity and toxicity of other therapeutic agents limit the available options and treatment. These investigators described the cases of 2 pregnant patients with corticosteroid-refractory immune thrombocytopenia who were successfully treated by romiplostim without any fetal or maternal complications. The authors concluded that romiplostim may represent an important alternative treatment choice during pregnancy for immune thrombocytopenia cases refractory to first-line therapy, especially because of its speed of action and high efficacy. Moreover, they stated that further data are needed to provide definitive evidence of its safety for newborns.
Furthermore, an UpToDate review on “Thrombocytopenia in pregnancy” (George and Knudtson, 2015) states that “The safety of thrombopoietin-receptor agonists (e.g., romiplostim, eltrombopag) during pregnancy is unknown”.
Thrombocytopenia following Allogeneic Stem Cell Transplantation:
Maximova et al (2015) examined the outcome of romiplostim for secondary failure of platelet recovery (SFPR) in children who had undergone hematopoietic stem cell transplantation (HSCT). A total of 7 transfusion-dependent pediatric patients (median age of 11 years), with platelet counts below 10 × 109/L, received 4 weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except 1 (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. The authors concluded that romiplostim could represent a beneficial first-line treatment, but further studies are needed.
Furthermore, an UpToDate review on “Hematopoietic support after hematopoietic cell transplantation” (Negrin, 2015) states that “With the approval of the thrombopoietic growth factors romiplostim and eltrombopag, additional studies are needed in the HCT setting to determine if these agents can effectively stimulate platelet production, reduce bleeding risks, and reduce transfusional requirements for platelets”.
|CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes.  Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 2015:|
|Other CPT codes related to the CPB: :|
|96372, 96374, 96375, 96376, 96379||Therapeutic, prophylactic, or diagnostic injection|
|HCPCS codes covered if selection criteria are met:|
|J2796||Injection, romiplostim, 10 mcg [Nplate]|
|ICD-10 codes covered if selection criteria are met:|
|D69.3||Immune thrombocytopenic purpura [idiopathic] [in members whose degree of thrombocytopenia and clinical condition increases the risk for bleeding and who have had an insufficient response to corticosteroids or immunoglobulins]|
|ICD-10 codes not covered for indications listed in the CPB:|
|B17.10 - B17.11||Acute hepatitis C|
|B18.2||Chronic viral hepatitis C|
|B19.20 - B19.21||Unspecified viral hepatitis C|
|D46.22, D46.c, D46.9||Myelodysplastic syndrome|
|D69.0 - D69.2
D69.41 - D69.9
|Purpura and other hemorrhagic conditions [thrombocytopenia associated with Evans syndrome]|
|D75.82||Heparin-induced thrombocytopenia (HIT)|
|D89.810 - D89.813||Graft-versus-host disease [associated with thrombocytopenia]|
|O72.3||Postpartum coagulation defects|
|O36.821+ - O36.829+||Fetal anemia and thrombocytopenia|
|O99.110 - O99.119||Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy [thrombocytopenia]|
|P61.0||Transient neonatal thrombocytopenia|
|T86.5||Complications of stem cell transplant [thrombocytopenia following allogeneic stem cell transplantation]|